Welcome to our dedicated page for Biohaven SEC filings (Ticker: BHVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biohaven Ltd. (NYSE: BHVN) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, shelf registration materials and other documents filed with the Securities and Exchange Commission. These filings offer detailed insight into Biohaven’s status as a global clinical-stage biopharmaceutical company focused on immunology, obesity, neuroscience and oncology.
Through its Form 8-K reports, Biohaven discloses material events such as underwritten public offerings of common shares, block share transactions under its at-the-market offering program, and updates on its New Drug Application for VYGLXIA (troriluzole) in spinocerebellar ataxia. Earnings-related 8-Ks furnish press releases summarizing quarterly financial results, R&D spending, and portfolio reprioritization decisions that concentrate resources on late-stage programs like opakalim, BHV-1300, BHV-1400 and taldefgrobep alfa.
Other filings reference the company’s effective Form S-3 shelf registration statement, prospectus supplements for equity offerings, and legal opinions related to share issuances. These documents outline the terms of capital raises used to fund Biohaven’s clinical pipeline, including its Kv7 ion channel modulators, MoDE and TRAP extracellular degraders, myostatin-activin pathway inhibitors, antibody-drug conjugates and TYK2/JAK1 inhibitor.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that explain the significance of each filing in clear language. Users can quickly understand the implications of financing transactions, regulatory updates, and clinical program disclosures without reading every technical detail. For deeper research, investors can review full-text filings to track trends in Biohaven’s operating expenses, trial progress and regulatory strategy over time.
Biohaven Ltd. director Kishan Mehta received a grant of 68,693 stock options on April 28, 2026. Each option gives the right to buy one common share at an exercise price of $9.61 and expires on April 28, 2036.
According to the vesting terms, all 68,693 options will vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, provided Mehta continues to serve with the company through that vesting date.
Biohaven Ltd. director Gregory Bailey reported receiving a grant of stock options as part of his compensation. The award covers 68,693 stock options, each allowing him to buy one common share at an exercise price of $9.61 per share.
The options vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, as long as he continues serving the company until that vesting date. After this grant, he holds 68,693 options directly, and this filing does not show any open-market buying or selling of shares.
Biohaven Ltd. director Michael Thomas Heffernan received a grant of stock options on April 28, 2026. The award covers 68,693 options, each allowing him to buy one common share at an exercise price of $9.61. After this grant, he holds 68,693 options directly.
These options vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, as long as he continues serving the company through that date. The options expire on April 28, 2036. This is a compensation-related grant rather than an open-market share purchase or sale.
Biohaven Ltd. director Irina Antonijevic received a grant of stock options covering 68,693 common shares, with an exercise price of 9.61 per share. These options vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, subject to her continuous service, and expire on April 28, 2036.
Biohaven Ltd. director John W. Childs reported a grant of stock options covering 68,693 Common Shares. The options have an exercise price of $9.61 per share, expire on April 28, 2036, and were received as a compensation award rather than an open‑market purchase.
These options will vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, provided Childs continues serving the company through that date. Following this grant, he holds 68,693 stock options directly.
Biohaven Ltd. director Robert J. Hugin received a grant of stock options, giving him the right to buy 68,693 common shares at an exercise price of $9.61 per share. These options vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, subject to his continuous service. After this award, he holds 68,693 stock options directly, with an expiration date of April 28, 2036.
Biohaven Ltd. director Julia P. Gregory received a grant of 68,693 stock options to buy Common Shares at an exercise price of $9.61 per share. The options expire on April 28, 2036 and represent compensation rather than an open-market purchase.
These options will vest in full on the earlier of April 28, 2027 or the date of Biohaven’s 2027 Annual Meeting of Shareholders, provided she continues serving the company through that vesting date. After this award, she holds 68,693 stock options directly.
Biohaven Ltd. director Kishan Mehta reported bona fide gift transfers of a total of 34,684 common shares on 2026-03-17. One transfer of 17,342 shares reduced his directly held stake to 5,320 common shares.
A separate 17,342-share transfer is shown as indirectly held by the “Kishen Mehta 21 Family Irrevocable Trust.” The trust is for the benefit of family members other than the reporting person, and Mehta disclaims beneficial ownership of the securities held by the trust.
Biohaven Ltd. is asking shareholders to approve three items at its 2026 annual meeting: elect three directors to serve until 2029, ratify Ernst & Young LLP as auditor for 2026, and approve on an advisory basis executive compensation.
The proxy highlights 2025 R&D progress, including extracellular protein degrader programs in IgA nephropathy and Graves’ disease, an epilepsy candidate opakalim with seizure reduction data, and obesity drug taldefgrobep entering Phase 2. Oncology antibody–drug conjugate programs and several discovery-stage assets are also described.
The board has eight members, six deemed independent, with a combined chair/CEO and a lead independent director. As of March 3, 2026, 150,420,584 common shares were outstanding; two institutional holders each own more than 5%. The company emphasizes financial discipline, equity ownership guidelines, and standard NYSE-aligned governance practices.
Biohaven Ltd. director John W. Childs reported an amended insider transaction showing an indirect open‑market purchase of 28,400 Common Shares by the John W Childs 2013 Revocable Trust at a weighted average price of $30.4266 per share.
The amendment corrects an earlier filing that had allocated 3,400 purchased shares to a 2013 Charitable Remainder Trust and 25,000 shares to the revocable trust. It clarifies that all 28,400 shares were acquired through the revocable trust, with no shares acquired through the charitable remainder trust in this transaction.